ABIVAX Société Anonyme (ENXTPA: ABVX)
Health Care · Biotechnology · FR
€101.80
-1.45% today · +55.7% 1Y
ABIVAX Société Anonyme (ENXTPA: ABVX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.12B and employs 80 people.
Over the last twelve months the share price has gained 55.7%, trading between 57.50 and 139.00.
Tweenvest scores ABIVAX Société Anonyme across four factors: quality 28/100, value 57/100. Its strongest factor is value.
ABVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.12B
- Revenue (TTM)
- $5.67M
- P/E
- —
- EPS
- -4.52
- Dividend yield
- —
- Beta (5Y)
- -0.23
- 52-week high
- €139.00
- 52-week low
- €57.50
- Avg volume (3M)
- —
- Shares outstanding
- 93.56M
- Employees
- 80
- Next earnings
- —
About ABIVAX Société Anonyme
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
- ISIN
- FR0012333284
- Founded
- 2013
- Listed since
- Jun 26, 2015
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.